

AMENDMENTS TO THE CLAIMS:

1-17. (canceled)

¹ ~~18.~~ (previously presented) An isolated polynucleotide consisting of a segment of SEQ ID NO:1, wherein the segment comprises a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence comprising 20 contiguous nucleotides of SEQ ID NO:1, wherein the 20 contiguous nucleotides include position 64331 of SEQ ID NO:1; and

(b) a nucleotide sequence which is entirely complementary to (a).

^{4.} ~~19.~~ (previously presented) An isolated polynucleotide consisting of a segment of SEQ ID NO:1, wherein the segment comprises a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence comprising 20 contiguous nucleotides of SEQ ID NO:1, wherein the 20 contiguous nucleotides include position 64331 of SEQ ID NO:1, and further wherein position 64331 of SEQ ID NO:1 is 'G'; and

(b) a nucleotide sequence which is entirely complementary to (a).

20-23. (canceled)

⁷ ~~24.~~ (previously presented) An isolated polynucleotide consisting of a segment of SEQ ID NO:1, wherein the segment comprises a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence comprising contiguous nucleotides of SEQ ID NO:1, wherein the contiguous nucleotides include both position 64331 of SEQ ID NO:1 and position 306382 of SEQ ID NO:1, and wherein position 64331 is 'A' and position 306382 is 'G'; and

(b) a nucleotide sequence which is entirely complementary to (a).

8 ~~25~~. (previously presented) An isolated polynucleotide consisting of a segment of SEQ ID NO:1, wherein the segment comprises a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence comprising contiguous nucleotides of SEQ ID NO:1, wherein the contiguous nucleotides include both position 64331 of SEQ ID NO:1 and position 306382 of SEQ ID NO:1, and wherein position 64331 is 'A' and position 306382 is 'C'; and
- (b) a nucleotide sequence which is entirely complementary to (a).

9 ~~26~~. (previously presented) An isolated polynucleotide consisting of a segment of SEQ ID NO:1, wherein the segment comprises a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence comprising contiguous nucleotides of SEQ ID NO:1, wherein the contiguous nucleotides include both position 64331 of SEQ ID NO:1 and position 306382 of SEQ ID NO:1, and wherein position 64331 is 'G' and position 306382 is 'G'; and
- (b) a nucleotide sequence which is entirely complementary to (a).

10 ~~27~~. (previously presented) An isolated polynucleotide consisting of a segment of SEQ ID NO:1, wherein the segment comprises a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence comprising contiguous nucleotides of SEQ ID NO:1, wherein the contiguous nucleotides include both position 64331 of SEQ ID NO:1 and position 306382 of SEQ ID NO:1, and wherein position 64331 is 'G' and position 306382 is 'C'; and
- (b) a nucleotide sequence which is entirely complementary to (a).

2 ~~28~~. (currently amended) The polynucleotide of claim ~~18~~¹, which is a single nucleotide polymorphism (SNP) detection reagent.

5 ~~29~~. (previously presented) The polynucleotide of claim ~~18~~⁴, which is a SNP detection reagent.

30-31. (canceled)

3
32. (previously presented) The detection reagent of claim ²~~28~~, wherein the SNP detection reagent is selected from the group consisting of probes, primers, allele-specific probes, allele-specific primers, detectably-labeled probes, and detectably-labeled primers.

6
33. (previously presented) The detection reagent of claim ⁵~~29~~, wherein the SNP detection reagent is selected from the group consisting of probes, primers, allele-specific probes, allele-specific primers, detectably-labeled probes, and detectably-labeled primers.

34-35. (canceled)